LIB Therapeutics Preparing To Launch New PCSK9 Inhibitor Option Lerochol

Solo US Launch, Ex-US Partners

 
• By Mandy Jackson
  
Lerochol is approved for hypercholesterolemia and HeFH, with a filing planned in HoFH (Shutterstock)

More from Strategy

More from Business